"Karcinom vaje\u010Dn\u00EDk\u016F spole\u010Dn\u011B s karcinomem vejcovod\u016F a prim\u00E1rn\u00EDmi n\u00E1dory peritonea je v \u010CR ro\u010Dn\u011B diagnostikov\u00E1n u p\u0159ibli\u017En\u011B 1 100 \u017Een, p\u0159i\u010Dem\u017E 70 % p\u0159\u00EDpad\u016F diagnostikov\u00E1no v pokro\u010Dil\u00E9m stadiu III nebo IV podle FIGO. I proto v\u00EDce ne\u017E 60 % \u017Een na toto onemocn\u011Bn\u00ED nakonec um\u00EDr\u00E1. Z\u00E1kladn\u00ED l\u00E9\u010Debnou modalitou je operace, jej\u00EDm\u017E c\u00EDlem je odstran\u011Bn\u00ED v\u0161ech n\u00E1dorov\u00FDch lo\u017Eisek, tj. dosa\u017Een\u00ED tzv. \u201Enulov\u00E9ho rezidua\u201C. Nezbytnou sou\u010D\u00E1st\u00ED prim\u00E1rn\u00ED l\u00E9\u010Dby je chemoterapie, av\u0161ak i p\u0159es pokroky v operativ\u011B a standardn\u00ED chemoterapii se v\u0161ak v posledn\u00EDch v\u00EDce ne\u017E 15 letech v\u00FDsledky nezlep\u0161uj\u00ED. \u0158ada studi\u00ED hledala nov\u00E9 mo\u017Enosti l\u00E9\u010Dby, kter\u00E9 by vedly ke zlep\u0161en\u00ED v\u00FDsledk\u016F. P\u0159id\u00E1n\u00ED t\u0159et\u00EDho cytostatika k dubletu carboplatina + paclitaxel v\u0161ak ke zlep\u0161en\u00ED v\u00FDsledk\u016F nevedlo. Dal\u0161\u00ED mo\u017Enost\u00ED je intraperitone\u00E1ln\u00ED l\u00E9\u010Dba. Tu hodnotilo n\u011Bkolik studi\u00ED, intraperitone\u00E1ln\u00ED l\u00E9\u010Dba sice vedla ke zlep\u0161en\u00ED v\u00FDsledk\u016F, ale vzhledem k toxicit\u011B je vhodn\u00E1 jen pro vybran\u00E9 pacientky. Na p\u0159elomu tis\u00EDcilet\u00ED se do l\u00E9\u010Dby n\u00E1dor\u016F postupn\u011B zav\u00E1d\u011Bj\u00ED c\u00EDlen\u00E9 l\u00E9ky. Tyto l\u00E9ky na rozd\u00EDl od chemoterapie p\u016Fsob\u00ED na jednotliv\u00E9 molekuly bun\u011B\u010Dn\u00FDch sign\u00E1ln\u00EDch kask\u00E1d. Jednou ze skupin c\u00EDlen\u00FDch l\u00E9k\u016F jsou i l\u00E9ky s antiangiogenn\u00EDm \u00FA\u010Dinkem, mezi n\u011B\u017E pat\u0159\u00ED tak\u00E9 bevacizumab \u2013 humanizovan\u00E1 monoklon\u00E1ln\u00ED protil\u00E1tka proti r\u016Fstov\u00E9mu faktoru c\u00E9vn\u00EDho endotelu (vascular endothelial growth factor \u2013 VEGF). Bevacizumab byl hodnocen u nemocn\u00FDch s karcinomem vaje\u010Dn\u00EDk\u016F v n\u011Bkolika studi\u00EDch II. f\u00E1ze v monoterapii i v kombinaci s chemoterapi\u00ED. V\u00FDsledky vedly k zah\u00E1jen\u00ED n\u011Bkolika studi\u00ED III. f\u00E1ze."@cs . "Bevacizumab v l\u00E9\u010Db\u011B karcinomu vaje\u010Dn\u00EDku"@cs . . "Ovarian together with salfinx carcinoma and primary peritoneal tumors are in CR diagnosed in 1100 women per year, when 70 % cases are already diagnosed at advanced stages III or IV according to FIGO. Therefore, more than 60% women die of this disease. The surgery represents the basic treatment modality to remove all the tumors and is ensued by chemotherapy. However despite the progress of standard chemotherapy and surgery, the therapy results have not advanced in last 15 years. Around the turn of the millennium, new targeted drugs are introduced into cancer therapy, which affect single molecules of signalling pathways. Bevacizumab \u2013 a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) belongs among targeted drugs with antiangiogenic properties. Bevacizumab was evaluated in ovarian carcinoma patients in phase II studies in monotherapy and combined with chemotherapy. The phase III studies were initiated."@en . "http://www.farmakoterapie.cz/c4064/bevacizumab-v-onkologicke-lecbe" . . . "Bevacizumab v l\u00E9\u010Db\u011B karcinomu vaje\u010Dn\u00EDku"@cs . "Karcinom vaje\u010Dn\u00EDk\u016F spole\u010Dn\u011B s karcinomem vejcovod\u016F a prim\u00E1rn\u00EDmi n\u00E1dory peritonea je v \u010CR ro\u010Dn\u011B diagnostikov\u00E1n u p\u0159ibli\u017En\u011B 1 100 \u017Een, p\u0159i\u010Dem\u017E 70 % p\u0159\u00EDpad\u016F diagnostikov\u00E1no v pokro\u010Dil\u00E9m stadiu III nebo IV podle FIGO. I proto v\u00EDce ne\u017E 60 % \u017Een na toto onemocn\u011Bn\u00ED nakonec um\u00EDr\u00E1. Z\u00E1kladn\u00ED l\u00E9\u010Debnou modalitou je operace, jej\u00EDm\u017E c\u00EDlem je odstran\u011Bn\u00ED v\u0161ech n\u00E1dorov\u00FDch lo\u017Eisek, tj. dosa\u017Een\u00ED tzv. \u201Enulov\u00E9ho rezidua\u201C. Nezbytnou sou\u010D\u00E1st\u00ED prim\u00E1rn\u00ED l\u00E9\u010Dby je chemoterapie, av\u0161ak i p\u0159es pokroky v operativ\u011B a standardn\u00ED chemoterapii se v\u0161ak v posledn\u00EDch v\u00EDce ne\u017E 15 letech v\u00FDsledky nezlep\u0161uj\u00ED. \u0158ada studi\u00ED hledala nov\u00E9 mo\u017Enosti l\u00E9\u010Dby, kter\u00E9 by vedly ke zlep\u0161en\u00ED v\u00FDsledk\u016F. P\u0159id\u00E1n\u00ED t\u0159et\u00EDho cytostatika k dubletu carboplatina + paclitaxel v\u0161ak ke zlep\u0161en\u00ED v\u00FDsledk\u016F nevedlo. Dal\u0161\u00ED mo\u017Enost\u00ED je intraperitone\u00E1ln\u00ED l\u00E9\u010Dba. Tu hodnotilo n\u011Bkolik studi\u00ED, intraperitone\u00E1ln\u00ED l\u00E9\u010Dba sice vedla ke zlep\u0161en\u00ED v\u00FDsledk\u016F, ale vzhledem k toxicit\u011B je vhodn\u00E1 jen pro vybran\u00E9 pacientky. Na p\u0159elomu tis\u00EDcilet\u00ED se do l\u00E9\u010Dby n\u00E1dor\u016F postupn\u011B zav\u00E1d\u011Bj\u00ED c\u00EDlen\u00E9 l\u00E9ky. Tyto l\u00E9ky na rozd\u00EDl od chemoterapie p\u016Fsob\u00ED na jednotliv\u00E9 molekuly bun\u011B\u010Dn\u00FDch sign\u00E1ln\u00EDch kask\u00E1d. Jednou ze skupin c\u00EDlen\u00FDch l\u00E9k\u016F jsou i l\u00E9ky s antiangiogenn\u00EDm \u00FA\u010Dinkem, mezi n\u011B\u017E pat\u0159\u00ED tak\u00E9 bevacizumab \u2013 humanizovan\u00E1 monoklon\u00E1ln\u00ED protil\u00E1tka proti r\u016Fstov\u00E9mu faktoru c\u00E9vn\u00EDho endotelu (vascular endothelial growth factor \u2013 VEGF). Bevacizumab byl hodnocen u nemocn\u00FDch s karcinomem vaje\u010Dn\u00EDk\u016F v n\u011Bkolika studi\u00EDch II. f\u00E1ze v monoterapii i v kombinaci s chemoterapi\u00ED. V\u00FDsledky vedly k zah\u00E1jen\u00ED n\u011Bkolika studi\u00ED III. f\u00E1ze." . "5134" . . "bevacizumab; ovarian carcinoma; targeted biological treatment"@en . "10" . "Farmakoterapie" . . "Bevacizumab v l\u00E9\u010Db\u011B karcinomu vaje\u010Dn\u00EDku" . "RIV/00209805:_____/14:#0000577" . "1"^^ . "2" . "1"^^ . . "Bevacizumab in the therapy of ovarian carcinoma"@en . . "[60B8FD2137A6]" . "Bevacizumab v l\u00E9\u010Db\u011B karcinomu vaje\u010Dn\u00EDku" . . "CZ - \u010Cesk\u00E1 republika" . . "Bevacizumab in the therapy of ovarian carcinoma"@en . . . . . . "RIV/00209805:_____/14:#0000577!RIV15-MSM-00209805" . . "P(ED2.1.00/03.0101)" . "3"^^ . "Chovanec, Josef" . "1801-1209" .